Jupiter Wellness Announces JW-300 Clinical Trial Results

Rhea-AI Summary

Jupiter Wellness, Inc. (NASDAQ:JUPW) announced promising results from a double-blind placebo-controlled trial of its JW-300 lotion for treating first-degree burns, including sunburn. The trial, involving 36 patients, showed a significant reduction in skin burns in those treated with JW-300 (27%) compared to the placebo group (61%) with a p-value of 0.047. The average erythema score was notably lower in the JW-300 group (0.388) versus the placebo (0.722). The burn care market, valued at $2.1 billion, is projected to grow at a CAGR of 7% from 2021 to 2028, indicating a strong market opportunity for JW-300.

Positive

• JW-300 significantly reduced burn incidence from UV exposure, with 27% of treated patients experiencing burns versus 61% in the placebo group.
• Average erythema score was lower in JW-300 patients (0.388) compared to placebo (0.722), indicating effective treatment.
• The burn care market's expected growth at a CAGR of 7% highlights the potential market opportunity for JW-300.
• JW-300 complements existing products like CaniSun™ and Photocil™, expanding Jupiter Wellness' product line.

Negative

• None.

JW-300 Demonstrates Efficacy in Treatment of Developing Burns (sunburn) in a Double-Blinded Placebo Controlled Clinical Trial.

JUPITER, FL / ACCESSWIRE / November 16, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), a wellness company specializing in the clinical development of skin therapeutics announced the results of a double-blinded placebo controlled trial of JW-300 for the treatment of first degree burns.

The JW-300 Clinical Trial included thirty-six patients who completed the study in which a controlled area of the skin was exposed to UV irradiation in the presence or absence (placebo) of the JW-300 lotion. The results demonstrated that the percent of subjects experiencing burns (measured by erythema) in patients treated with JW-300 was significantly lower (p=0.047) than in subjects receiving the placebo lotion. The percent of subjects that were burned in the placebo arm was 61% compared to 27% in patients treated with the JW-300. In addition, patients (n=18) treated with JW-300 the average erythema score was 0.388 after radiation compared to 0.722 in the placebo arm (n=18).

"These encouraging results show the potential of JW-300 for the prevention and potentially the treatment of burns including sunburn," stated Jupiter Wellness Chief Scientific Officer, Dr. Glynn Wilson. "JW-300 complements and has the potential to expand our current product lines which include CaniSun™ and Photocil™ that are clinically proven and designed to protect, treat, and achieve therapeutic balance in skincare health. The treatment of burns including sunburn are important indications with unmet needs, particularly in the OTC market where we see a significant opportunity for JW-300."

The burn care market was valued at $2.1 billion in 2020 and is expected to grow at a CAGR of 7% from 2021 to 2028 driven by rising incidence of burns, favorable reimbursement policies, and technological advancement.

About Jupiter Wellness
Jupiter Wellness, Inc. (NASDAQ:JUPW) is a leading developer of skincare therapeutics and treatments. The Company's product pipeline of enhanced skincare therapeutics focuses on the endocannabinoid system to address indications including psoriasis, eczema, burns, herpes cold sores, and skin cancer. Jupiter generates revenue from a growing line of proprietary over-the-counter skincare products including its CaniSun™ sunscreen and other wellness brands sold through www.cbdcaring.com.

For additional information, please visit www.jupiterwellness.com. The Company's public filings can be found at www.Sec.gov.

Safe Harbor Statement
To the extent any statements contained in this presentation of Jupiter Wellness, Inc. (the "Company") contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 and the information that are based upon beliefs of, and information currently available to, the company's management as well as estimates and assumptions made by the company's management. These statements can be identified by the fact that they do not relate strictly to historic or current facts. When used in this presentation the words "estimate," "expect," intend," believe," plan," "anticipate," "projected" and other words or the negative of these terms and similar expressions as they relate to the company or the company's management identify forward-looking statements. Such statements reflect the current view of the company with respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to the company's industry, its operations and results of operations and any businesses that may be acquired by the company. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the company believes that the expectations reflected in the forward-looking statements are reasonable, the company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the security laws of the United States, the company does not intend to update any of the forward-looking statements to conform these statements to actual results.

Investor & Public Relations Contact Info
Phone: 561-462-2700
Email: info@JupiterWellness.com

SOURCE: Jupiter Wellness, Inc.

View source version on accesswire.com:
https://www.accesswire.com/672995/Jupiter-Wellness-Announces-JW-300-Clinical-Trial-Results

FAQ

What are the results of the JW-300 clinical trial?

The JW-300 clinical trial showed that only 27% of patients treated experienced burns, compared to 61% in the placebo group, indicating significant efficacy.

What is the significance of JW-300's average erythema score?

Patients treated with JW-300 had an average erythema score of 0.388, significantly lower than the placebo group score of 0.722, suggesting better skin protection.

What is the market potential for JW-300?

The burn care market was valued at $2.1 billion and is projected to grow at a CAGR of 7% from 2021 to 2028, presenting significant opportunities for JW-300.

What does the trial indicate about JW-300's application?

The trial results indicate that JW-300 has potential for both prevention and treatment of burns, particularly sunburn.